Glioblastoma (GBM; IDH-wild type glioma, grade 4) is the most aggressive glioma and despite intensive conventional therapy which includes surgery, radiation, and both concurrent and adjuvant temozolomide (TMZ) chemotherapy, GBM remains treatment-resistant and disease progression is fatal, with a median survival below 15 months2. The gene discussed is IDH1; the disease is central nervous system cancer.